LUTETIUM TEXAPHYRIN (PCT-0123) INJECTION IN PHOTODYNAMIC TREATMENT

光动力治疗中的镥泰克萨菲林 (PCT-0123) 注射液

• 批准号: 6115043
• 负责人: SANDRA J. HORNING
• 金额: $ 4.03万
• 依托单位: STANFORD UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 1998
• 资助国家: 美国
• 起止时间: 1998-12-01 至 1999-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6115043
• 关键词: breast neoplasms; clinical research; clinical trial phase I; dosage; drug adverse effect; drug screening /evaluation; human subject; human therapy evaluation; injection /infusion; lasers; neoplasm /cancer photoradiation therapy; photosensitizing agents; skin neoplasms

Lu-Tex is a photosensitizer with an absorption peak at 732 nm, a wavelength capable of penetrating tissue and melanin. Patients with unresectable metatstatic cancer of the skin or subcutaneous tissue received a single IV injection of Lu-Tex, followed 3-8 hours later by light treatment of lesions (732 nm, 75 mW/cm2, 150 J/cm2). Lu-Tex doses were escalated from 0.5 to 6.2 umol/kg in 7 cohorts. Light was delivered by a laser or light emitting diode.

Lu-Tex是在732 nm处具有吸收峰的光敏剂， 波长能够穿透组织和黑色素。患者 不能切除的皮肤或皮下组织转移癌 接受单次静脉注射Lu-Tex，3-8小时后， 病变的光治疗（732 nm，75 mW/cm 2，150 J/cm 2）。Lu-Tex剂量 在7个队列中从0.5 μ mol/kg递增至6.2 μ mol/kg。光 通过激光器或发光二极管传送。